drugset
drugset / Trial / NCT05894928

A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants

NCT05894928 ↗

Phase 1 Completed 21 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
RandomizedCrossoverOpen-labelBasic science

Summary

The main purpose of this study is to conduct blood tests to measure how much LOXO-783 is in the bloodstream and how the body handles and eliminates LOXO-783 when administered alone or in combination with cholestyramine in healthy participants. The study will also evaluate the safety and tolerability of LOXO-783 with and without cholestyramine. Participation could last up to 63 days including screening period.

Timeline

Start
2023-06-07
Primary completion
2023-07-09
Completion
2023-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholestyramine Other / unclassified — Oral
Subject LOXO-783 Unknown — Oral

Indications

No indication recorded.